Antigen delivery systems ii. development of live recombinant attenuated bacterial antigen and dna vaccine delivery vector vaccines

Roy Curtiss

Research output: Chapter in Book/Report/Conference proceedingChapter

20 Citations (Scopus)

Abstract

The development of safe, efficacious recombinant attenuated bacterial antigen delivery systems requires attention to some desired attributes. The vaccine design should be focused on-enhancing immunogenicity and the magnitude and duration of the immune response to the expressed protective antigen, and on diminishing the potentially competing immune responses to antigens of the attenuated bacterial antigen delivery vector. Depending upon the disease to be prevented and the nature of the pathogen causing that disease-it may be necessary to make genetic modifications of the antigen delivery system, to maximize a Th2 response important for inducing mucosal and systemic antibody responses or, in other cases, a Th1 response to enhance the cellular immunity. It is potentially desirable to introduce biological containment features into vaccines to prevent their survival and persistence in environments into which they might be introduced as a consequence of immunization. The magnitude of protective immunity to an expressed protective antigen in regard to mucosal and systemic antibody responses, is more or less dependent on the amount of protective antigen delivered to the immunized host.

Original languageEnglish (US)
Title of host publicationMucosal Immunology, Two-Volume Set
PublisherElsevier Inc.
Pages1009-1037
Number of pages29
ISBN (Print)9780124915435
DOIs
StatePublished - 2005

Fingerprint

Bacterial Antigens
Vaccines
Antigens
Antibody Formation
Containment of Biohazards
Histocompatibility Antigens Class II
Cellular Immunity
Immunity
Immunization

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Antigen delivery systems ii. development of live recombinant attenuated bacterial antigen and dna vaccine delivery vector vaccines. / Curtiss, Roy.

Mucosal Immunology, Two-Volume Set. Elsevier Inc., 2005. p. 1009-1037.

Research output: Chapter in Book/Report/Conference proceedingChapter

Curtiss, Roy. / Antigen delivery systems ii. development of live recombinant attenuated bacterial antigen and dna vaccine delivery vector vaccines. Mucosal Immunology, Two-Volume Set. Elsevier Inc., 2005. pp. 1009-1037
@inbook{5d35e87339f848dbbdd17b7c2544809b,
title = "Antigen delivery systems ii. development of live recombinant attenuated bacterial antigen and dna vaccine delivery vector vaccines",
abstract = "The development of safe, efficacious recombinant attenuated bacterial antigen delivery systems requires attention to some desired attributes. The vaccine design should be focused on-enhancing immunogenicity and the magnitude and duration of the immune response to the expressed protective antigen, and on diminishing the potentially competing immune responses to antigens of the attenuated bacterial antigen delivery vector. Depending upon the disease to be prevented and the nature of the pathogen causing that disease-it may be necessary to make genetic modifications of the antigen delivery system, to maximize a Th2 response important for inducing mucosal and systemic antibody responses or, in other cases, a Th1 response to enhance the cellular immunity. It is potentially desirable to introduce biological containment features into vaccines to prevent their survival and persistence in environments into which they might be introduced as a consequence of immunization. The magnitude of protective immunity to an expressed protective antigen in regard to mucosal and systemic antibody responses, is more or less dependent on the amount of protective antigen delivered to the immunized host.",
author = "Roy Curtiss",
year = "2005",
doi = "10.1016/B978-012491543-5/50060-7",
language = "English (US)",
isbn = "9780124915435",
pages = "1009--1037",
booktitle = "Mucosal Immunology, Two-Volume Set",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Antigen delivery systems ii. development of live recombinant attenuated bacterial antigen and dna vaccine delivery vector vaccines

AU - Curtiss, Roy

PY - 2005

Y1 - 2005

N2 - The development of safe, efficacious recombinant attenuated bacterial antigen delivery systems requires attention to some desired attributes. The vaccine design should be focused on-enhancing immunogenicity and the magnitude and duration of the immune response to the expressed protective antigen, and on diminishing the potentially competing immune responses to antigens of the attenuated bacterial antigen delivery vector. Depending upon the disease to be prevented and the nature of the pathogen causing that disease-it may be necessary to make genetic modifications of the antigen delivery system, to maximize a Th2 response important for inducing mucosal and systemic antibody responses or, in other cases, a Th1 response to enhance the cellular immunity. It is potentially desirable to introduce biological containment features into vaccines to prevent their survival and persistence in environments into which they might be introduced as a consequence of immunization. The magnitude of protective immunity to an expressed protective antigen in regard to mucosal and systemic antibody responses, is more or less dependent on the amount of protective antigen delivered to the immunized host.

AB - The development of safe, efficacious recombinant attenuated bacterial antigen delivery systems requires attention to some desired attributes. The vaccine design should be focused on-enhancing immunogenicity and the magnitude and duration of the immune response to the expressed protective antigen, and on diminishing the potentially competing immune responses to antigens of the attenuated bacterial antigen delivery vector. Depending upon the disease to be prevented and the nature of the pathogen causing that disease-it may be necessary to make genetic modifications of the antigen delivery system, to maximize a Th2 response important for inducing mucosal and systemic antibody responses or, in other cases, a Th1 response to enhance the cellular immunity. It is potentially desirable to introduce biological containment features into vaccines to prevent their survival and persistence in environments into which they might be introduced as a consequence of immunization. The magnitude of protective immunity to an expressed protective antigen in regard to mucosal and systemic antibody responses, is more or less dependent on the amount of protective antigen delivered to the immunized host.

UR - http://www.scopus.com/inward/record.url?scp=84882870003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882870003&partnerID=8YFLogxK

U2 - 10.1016/B978-012491543-5/50060-7

DO - 10.1016/B978-012491543-5/50060-7

M3 - Chapter

SN - 9780124915435

SP - 1009

EP - 1037

BT - Mucosal Immunology, Two-Volume Set

PB - Elsevier Inc.

ER -